GlassScriptPhysician profile
Eric R Lohman
NPI 1801863873
$6,005.70
in general payments reported to CMS, 2019-2025
30 companies · $819 in 2025
The $819 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $654 · 2020: $522 · 2021: $1,124 · 2022: $685 · 2023: $1,254 · 2024: $948 · 2025: $819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,021.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,021.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,001.55 | 2019-2025 | |
| Abbott Laboratories | $959.54 | 2019-2025 | Gallant, Assurity, Aveir |
| Amgen INC. | $477.68 | 2019-2025 | Repatha, Repatha |
| Medtronic, INC. | $405.79 | 2021-2025 | Onyx Frontier, Symplicity G3, Linq II |
| Abiomed | $395.99 | 2024-2025 | Impella |
| Pfizer INC. | $369.84 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $357.23 | 2019-2025 | Lifevest |
| Boston Scientific Corporation | $268.31 | 2021-2024 | Bodyguardian |
| Merck Sharp & Dohme LLC | $250.65 | 2021-2025 | Verquvo |
| Astrazeneca Pharmaceuticals LP | $239.61 | 2019-2025 | Brilinta, Farxiga |
| Shockwave Medical, INC | $235.92 | 2022-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Janssen Pharmaceuticals, INC | $214.78 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $105.24 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $98.50 | 2024-2025 | |
| Medtronic Vascular, INC. | $96.32 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $88.80 | 2020-2021 | |
| Novo Nordisk INC | $84.43 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $79.90 | 2019-2024 | Evkeeza |
| Kowa Pharmaceuticals America, INC. | $58.25 | 2019-2021 | |
| Atricure, INC. | $54.07 | 2024-2025 | Atriclip Laa Exclusion System |
| Esperion Therapeutics, INC. | $26.51 | 2021 | |
| Irhythm Technologies, INC. | $21.06 | 2022 | |
| Angiodynamics, INC. | $20.67 | 2024 | Auryon Laser System 100-120 Vac |
| Cook Medical LLC | $18.26 | 2020 | |
| Vivaquant INC, Dba Rhythm Express | $16.50 | 2025 | Rhythm Express |
| Acist Medical Systems, INC. | $16.14 | 2019 | |
| Getinge USA Sales, LLC | $15.82 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.83 | 2020 | |
| Allergan, INC. | $11.27 | 2019 | |
| Bardy Diagnostics, INC. | $5.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Lohman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.